International ophthalmology · 2026
Preserflo microshunt in a real-life UK tertiary setting: success rates, safety profile, and postoperative management.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fossati Giovanni, Trevisi Marco, Sodeinde Modupe, Pagano Luca, Romano Mario R, Osman Lina, Sarodia Usman, Malick Huzaifa
Аннотация
PURPOSE: To evaluate the efficacy and safety of PreserFlo MicroShunt in a UK tertiary glaucoma centre at one year follow-up.
METHODS: this is a retrospective, single-centre study of eyes with glaucoma that underwent PreserFlo MicroShunt implantation. Success was defined as IOP between 6 and 21 mmHg (range 6-17 and 6-14 mmHg was also evaluated) and a reduction of at least 20% of preoperative IOP; success was defined as complete (CS) if without hypotensive medications, and as overall (OS), if with or without medications. Secondary outcomes included final IOP, final number of glaucoma drops, final BCVA.
RESULTS: a total of 69 eyes were included in the study. The CS and OS for IOP 6-21 mmHg were achieved in 73.9% and 79.7%, respectively. For the range of IOP 6-17 mmHg, 72.5% and 78.3%, and for the range of IOP 6-14 mmHg, 55.1% and 58.0%. The mean IOP was significantly reduced from 24.7 ± 7.2 mmHg at baseline to 12.4 ± 5.0 mmHg (p < 0.0001). The most frequent adverse event was transient early hypotony (28.9%), followed by hyphaema (11.5%) and choroidal effusion (8.6%). Aqueous misdirection occurred in two pseudophakic eyes with primary angle-closure glaucoma (PACG), representing a rare but vision-threatening complication in this setting.
CONCLUSION: PreserFlo MicroShunt was effective and safe in the follow-up period and achieved IOP results in the low teens.
METHODS: this is a retrospective, single-centre study of eyes with glaucoma that underwent PreserFlo MicroShunt implantation. Success was defined as IOP between 6 and 21 mmHg (range 6-17 and 6-14 mmHg was also evaluated) and a reduction of at least 20% of preoperative IOP; success was defined as complete (CS) if without hypotensive medications, and as overall (OS), if with or without medications. Secondary outcomes included final IOP, final number of glaucoma drops, final BCVA.
RESULTS: a total of 69 eyes were included in the study. The CS and OS for IOP 6-21 mmHg were achieved in 73.9% and 79.7%, respectively. For the range of IOP 6-17 mmHg, 72.5% and 78.3%, and for the range of IOP 6-14 mmHg, 55.1% and 58.0%. The mean IOP was significantly reduced from 24.7 ± 7.2 mmHg at baseline to 12.4 ± 5.0 mmHg (p < 0.0001). The most frequent adverse event was transient early hypotony (28.9%), followed by hyphaema (11.5%) and choroidal effusion (8.6%). Aqueous misdirection occurred in two pseudophakic eyes with primary angle-closure glaucoma (PACG), representing a rare but vision-threatening complication in this setting.
CONCLUSION: PreserFlo MicroShunt was effective and safe in the follow-up period and achieved IOP results in the low teens.